TARS · Insider Trading
Tarsus Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by TARS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | WENDY L YARNO | Director | M | — | — |
| 2026-09-17 | DAVID E I PYOTT | Director | M | — | — |
| 2026-09-17 | WILLIAM J PHD LINK | Director | MIXED | — | — |
| 2026-09-09 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | — | — |
| 2026-09-09 | Bobak R. Azamian | President/CEO and Board Chair | Sell | — | — |
| 2026-09-09 | Seshadri Neervannan | Chief Operating Officer | Sell | — | — |
| 2026-09-03 | Bobak R. Azamian | President/CEO and Board Chair | Sell | — | — |
| 2026-09-03 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | — | — |
| 2026-06-29 | BHASKAR CHAUDHURI | Director | A | — | — |
| 2026-06-29 | Scott W Morrison | Director | A | — | — |
| 2026-06-29 | DAVID E I PYOTT | Director | A | — | — |
| 2026-06-29 | Katherine Goodrich | Director | A | — | — |
| 2026-06-29 | Andrew D. Goldberg | Director | A | — | — |
| 2026-06-29 | WILLIAM J PHD LINK | Director | A | — | — |
| 2026-06-29 | WENDY L YARNO | Director | A | — | — |
| 2026-06-22 | Bobak R. Azamian | President/CEO and Board Chair | Sell | — | — |
| 2026-06-17 | Jeffrey S Farrow | See Remarks | MIXED | — | — |
| 2026-06-17 | WILLIAM J PHD LINK | Director | Sell | — | — |
| 2026-06-17 | Katherine Goodrich | Director | Sell | — | — |
| 2026-06-16 | Andrew D. Goldberg | Director | M | — | — |
| 2026-06-16 | BHASKAR CHAUDHURI | Director | M | — | — |
| 2026-06-16 | Scott W Morrison | Director | M | — | — |
| 2026-06-16 | WILLIAM J PHD LINK | Director | M | — | — |
| 2026-06-16 | WENDY L YARNO | Director | M | — | — |
| 2026-06-16 | Katherine Goodrich | Director | M | — | — |
| 2026-04-28 | DAVID E I PYOTT | Director | M | — | — |
| 2026-03-24 | Seshadri Neervannan | Chief Operating Officer | Sell | — | — |
| 2026-03-19 | Bryan Wahl | General Counsel | Sell | — | — |
| 2026-03-19 | Seshadri Neervannan | Chief Operating Officer | Sell | — | — |
| 2026-03-19 | Dianne C. Whitfield | Chief Human Resources Officer | Sell | — | — |
| 2026-03-19 | Jeffrey S Farrow | See Remarks | Sell | — | — |
| 2026-03-19 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | — | — |
| 2026-03-19 | Aziz Mottiwala | Chief Commercial Officer | Sell | — | — |
| 2026-03-19 | Bobak R. Azamian | President/CEO and Board Chair | Sell | — | — |
| 2026-03-18 | WILLIAM J PHD LINK | Director | Sell | — | — |
| 2026-03-17 | Jeffrey S Farrow | See Remarks | M | — | — |
| 2026-03-17 | Bryan Wahl | General Counsel | M | — | — |
| 2026-03-17 | Dianne C. Whitfield | Chief Human Resources Officer | M | — | — |
| 2026-03-17 | Aziz Mottiwala | Chief Commercial Officer | M | — | — |
| 2026-03-17 | Elizabeth Yeu Lin | Chief Medical Officer | M | — | — |
| 2026-03-17 | Bobak R. Azamian | President/CEO and Board Chair | M | — | — |
| 2026-03-17 | Seshadri Neervannan | Chief Operating Officer | M | — | — |
| 2026-03-09 | Jeffrey S Farrow | See Remarks | A | — | — |
| 2026-03-09 | Elizabeth Yeu Lin | Chief Medical Officer | A | — | — |
| 2026-03-09 | Bobak R. Azamian | President/CEO and Board Chair | A | — | — |
| 2026-03-09 | Bryan Wahl | General Counsel | A | — | — |
| 2026-03-09 | Seshadri Neervannan | Chief Operating Officer | A | — | — |
| 2026-03-09 | Dianne C. Whitfield | Chief Human Resources Officer | A | — | — |
| 2026-03-09 | Aziz Mottiwala | Chief Commercial Officer | A | — | — |
| 2026-03-05 | Seshadri Neervannan | Chief Operating Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,714,036 | — |
| — | 10%+ Owner | 3,153,015 | — |
| — | 10%+ Owner | 2,013,601 | — |
| — | 10%+ Owner | 1,917,157 | — |
| — | 10%+ Owner | 1,795,334 | — |
| — | Director | 1,752,183 | — |
| — | Director | 1,308,273 | — |
| — | President/CEO and Board Chair | 861,412 | — |
| — | Director | 94,553 | — |
| — | Chief Operating Officer | 79,007 | — |
| — | General Counsel | 72,315 | — |
| — | Chief Commercial Officer | 70,250 | — |
| — | See Remarks | 56,801 | — |
| — | Chief Human Resources Officer | 35,028 | — |
| — | Chief Financial Officer | 26,785 | — |
| — | Director | 19,654 | — |
| — | Director | 16,956 | — |
| — | Director | 13,654 | — |
| — | Director | 11,654 | — |
| — | Director | 10,958 | — |
| — | Chief Medical Officer | 9,523 | — |
| — | Director | 5,350 | — |
| — | V.P., Clinical Affairs | 3,191 | — |
| — | CHIEF MEDICAL OFFICER | 2,251 | — |
| — | Director | 2,233 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TARS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.